Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

Kyle Blankenship

A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway